Ligand Pharmaceuticals Inc expected to post earnings of 66 cents a share - Earnings Preview

Ligand Pharmaceuticals Incorporated

23/02/2024 16:17

* Ligand Pharmaceuticals Inc  LGND.OQ   LGND.O  is expected
to show a fall in quarterly revenue when it reports  results on
February 27 for the period ending December 31 2023
    * The San Diego California-based  company is expected to
report a
45.3% decrease in revenue to $25.716 million from $47.04 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Ligand Pharmaceuticals
Inc is
for earnings of 66 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ligand
Pharmaceuticals Inc is $110.00​, above​ its last closing price
of $73.56. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.60        0.61       1.02      Beat    67.2
 Jun. 30 2023  0.64        0.64       1.42      Beat    122
 Mar. 31 2023  0.95        0.89       2.28      Beat    155​
 Dec. 31 2022  1.18        1.19       1.36      Beat    14
 ​​Sep.        0.44        0.43       1.31      Beat    203.4
 30 2022                                                
 Jun. 30 2022  0.46        0.43       1.03      Beat    139.5​
 Mar. 31 2022  0.66        0.66       0.58      Missed  -11.7
 Dec. 31 2021  1.37        1.37       1.80      Beat    31.4
 This summary was machine generated February 23 at 16:17 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)